Resistance to dual blockade of the kinases PI3K and mTOR in KRAS -mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR-Reference-Cited by-同舟云学术

Resistance to dual blockade of the kinases PI3K and mTOR in KRAS -mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR

Published:2014-11-11 Issue:351 Volume:7 Page:
ISSN:1945-0877
Container-title:Science Signaling
language:en
Short-container-title:Sci. Signal.

Author:

Belmont Peter J.¹,Jiang Ping¹,McKee Trevor D.²,Xie Tao¹,Isaacson Jason¹,Baryla Nicole E.³,Roper Jatin⁴,Sinnamon Mark J.⁴,Lee Nathan V.¹,Kan Julie L. C.¹,Guicherit Oivin¹,Wouters Bradly G.²³,O’Brien Catherine A.⁵,Shields David¹,Olson Peter¹,VanArsdale Todd¹,Weinrich Scott L.¹,Rejto Paul¹,Christensen James G.¹,Fantin Valeria R.¹,Hung Kenneth E.⁶,Martin Eric S.¹

Affiliation:

1. Oncology Research Unit, Pfizer Global Research and Development, San Diego, CA 92121, USA.

2. Departments of Radiation Oncology and Medical Biophysics, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2M9, Canada.

3. Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada.

4. Division of Gastroenterology, Department of Medicine, Tufts Medical Center, Boston, MA 02111, USA.

5. University Health Network, University of Toronto, Toronto, Ontario M5G 2M9, Canada.

6. Pfizer Biotherapeutics Clinical Research, Cambridge, MA 02140, USA.

Abstract

Combination therapy with EGFR inhibitors may overcome acquired resistance to PI3K pathway inhibitors in some colorectal cancer patients.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference62 articles.

1. Targeted therapies: A new generation of cancer treatments;Gerber D. E.;Am. Fam. Physician,2008

2. Targeting the cancer kinome through polypharmacology

3. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST);Hochhaus A.;Ann. Hematol.,2004

4. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

5. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance;Nature Cancer;2024-07-11

2. HMGA1 sensitizes esophageal squamous cell carcinoma to mTOR inhibitors through the ETS1-FKBP12 axis;International Journal of Biological Sciences;2024

3. Small-molecule drugs of colorectal cancer: Current status and future directions;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-01

4. mTOR inhibition suppresses salinomycin-induced ferroptosis in breast cancer stem cells by ironing out mitochondrial dysfunctions;Cell Death & Disease;2023-11-15

5. Breast cancer: miRNAs monitoring chemoresistance and systemic therapy;Frontiers in Oncology;2023-06-16